Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record.

Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial

Open access
Gershlick, Anthony, De Scheerder, Ivan, Chevalier, Bernard, Stephens-Lloyd, Amanda, Camenzind, Edoardo, Vrints, Christian, Reifart, Nicolaus, Missault, Luc, Goy, Jean-Jacques, Brinker, Jeffrey A., Raizner, Albert E., Urban, Philip, Heldman, Alan W. · 2004 · Circulation

Abstract

Background— The use of a stent to deliver a drug may reduce in-stent restenosis. Paclitaxel interrupts the smooth muscle cell cycle by stabilizing microtubules, thereby arresting mitosis. Methods and Results— On the basis of prior animal studies, the European evaLUation of the pacliTaxel Eluting Stent (ELUTES) pilot clinical trial (n=190) investigated the safety and efficacy of V-Flex Plus coronary stents (Cook Inc) coated with escalating doses of paclitaxel (0.2, 0.7, 1.4, and 2.7 μg/mm 2 stent surface area) applied directly to the abluminal surface of the stent in de novo lesions compared with bare stent alone. The primary efficacy end point was angiographic percent diameter stenosis at 6 months. At angiographic follow-up, percent diameter stenosis was 33.9±26.7% in controls (n=34) and 14.2±16.6% in the 2.7-μg/mm 2 group (n=31; P =0.006). Late loss decreased from 0.73±0.73 to 0.11±0.50 mm ( P =0.002). Binary restenosis (≥50% at follow-up) decreased from 20.6% to 3.2% ( P =0.056), with no significant benefit from intermediate paclitaxel doses. Freedom from major adverse cardiac events in the highest (effective) dose group was 92%, 89%, and 86% at 1, 6, and 12 months, respectively ( P =NS versus control). No late stent thromboses were seen in any treated group despite clopidogrel treatment for 3 months only. Conclusions— Paclitaxel applied directly to the abluminal surface of a bare metal coronary stent, at a dose density of 2.7 μg/mm 2 , reduced angiographic indicators of in-stent restenosis without short- or medium-term side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000109694.58299.a0

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 237

Metadata

Authors
Gershlick, A., De Scheerder, I., Chevalier, B., Stephens-Lloyd, A., Camenzind, E., Vrints, C., Reifart, N., Missault, L., Goy, J.-J., Brinker, J. A., Raizner, A. E., Urban, P., & Heldman, A. W.
Venue
Circulation
Published
2004-02-03
Volume
109
Issue
4
Pages
487-493
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2104336889
Cited by
237
References
0
FWCI
38.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial. https://app.cochat.ai/papers/10.1161/01.cir.0000109694.58299.a0
The paper
Gershlick, A., De Scheerder, I., Chevalier, B., Stephens-Lloyd, A., Camenzind, E., Vrints, C., Reifart, N., Missault, L., Goy, J.-J., Brinker, J. A., Raizner, A. E., Urban, P., & Heldman, A. W. (2004). Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial. Circulation. https://doi.org/10.1161/01.cir.0000109694.58299.a0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.